Edgar Filing: Pharma-Bio Serv, Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 31, 2009

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to ______________

Commission File No. 000-50956

PHARMA-BIO SERV, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	20-0653570
(State or Other Jurisdiction of Incorporation or Organization)	(IRS Employer Identification No.)

Pharma-Bio Serv Building, Industrial Zone Lot 14, Barrio Higuillar, Dorado, Puerto Rico	00646 (Zip Code)
(Address of Principal Executive Offices)

Registrant’s Telephone Number, Including Area Code 787-278-2709

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

	Large accelerated filer ¨	Accelerated filer ¨
	Non-accelerated filer ¨	Smaller reporting companyx

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x

The number of shares of the registrant’s common stock outstanding as of September 11, 2009 was 20,751,215.

PHARMA-BIO SERV, INC.

FORM 10-Q

FOR THE QUARTER ENDED JULY 31, 2009

TABLE OF CONTENTS

	Page
PART I FINANCIAL INFORMATION

Item 1 – Financial Statements		3

Condensed Consolidated Balance Sheets as of July 31, 2009 and October 31, 2008 (unaudited)		3

Condensed Consolidated Statements of Income for the three-month periods and nine-month periods ended July 31, 2009 and 2008 (unaudited)		4

Condensed Consolidated Statements of Cash Flows for the three-month periods and the nine-month periods ended July 31, 2009 and 2008 (unaudited)		5

Notes to Condensed Consolidated Financial Statements (unaudited)		6

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations		12

Item 4 – Controls and Procedures		17

PART II OTHER INFORMATION

Item 1 – Legal Proceedings		18

Item 6 – Exhibits		18

SIGNATURES		19

-2-

PART I – FINANCIAL INFORMATION

Item 1.

FINANCIAL STATEMENTS

PHARMA-BIO SERV, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

	July 31, 2009 *			October 31, 2008 **
ASSETS:
Current assets
Cash and cash equivalents	$	2,150,412		$	3,087,990
Accounts receivable		2,242,707			3,245,153
Other		284,874			194,108
Total current assets		4,677,993			6,527,251

Property and equipment		1,553,880			1,521,575
Other assets		107,997			63,127
Total assets	$	6,339,870		$	8,111,953

LIABILITIES AND STOCKHOLDERS’ EQUITY:
Current liabilities
Current portion-obligations under capital leases	$	47,610		$	45,318
Accounts payable and accrued expenses		1,120,225			1,189,705
Due to affiliate		500,000			2,706,892
Income taxes payable		157,444			48,324
Total current liabilities		1,825,279			3,990,239

Obligations under capital leases, less current portion		67,107			69,934
Total liabilities		1,892,386			4,060,173
Stockholders' equity:
Preferred Stock, $0.0001 par value; authorized 10,000,000 shares; none outstanding		-			-
Common Stock, $0.0001 par value; authorized 50,000,000 shares; issued and outstanding 20,751,215 shares		2,075			2,075
Additional paid-in capital		587,593			540,337
Retained earnings		3,874,746			3,534,060
Accumulated other comprehensive loss		(16,930	)		(24,692	)
Total stockholders' equity		4,447,484			4,051,780
Total liabilities and stockholders' equity	$	6,339,870		$	8,111,953

*	Unaudited.
**	Condensed from audited financial statements.

See notes to condensed consolidated financial statements.

-3-

PHARMA-BIO SERV, INC.

Condensed Consolidated Statements of Income

(Unaudited)

	Three months ended July 31,						Nine months ended July 31,
	2009			2008			2009			2008
REVENUES	$	2,626,531		$	4,191,873		$	8,659,944		$	11,493,969

COST OF SERVICES		1,753,351			2,547,992			5,732,323			7,129,868

GROSS PROFIT		873,180			1,643,881			2,927,621			4,364,101

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES		710,050			802,194			2,208,698			2,304,118

INCOME FROM OPERATIONS		163,130			841,687			718,923			2,059,983

OTHER INCOME (EXPENSES):
Interest expense		(4,484	)		(46,670	)		(50,811	)		(179,988	)
Interest income		4,988			11,492			20,971			69,364
Gain on disposition of property and equipment		-			-			6,081			-
		504			(35,178	)		(23,759	)		(110,624	)

INCOME BEFORE TAXES		163,634			806,509			695,164			1,949,359

INCOME TAXES		110,345			291,631			354,478			806,574

NET INCOME	$	53,289		$	514,878		$	340,686		$	1,142,785

BASIC EARNINGS PER COMMON SHARE	$	0.003		$	0.026		$	0.016		$	0.058

DILUTED EARNINGS PER COMMON SHARE	$	0.002		$	0.023		$	0.015		$	0.052

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – BASIC		20,751,215			19,892,186			20,751,215			19,708,428

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – DILUTED		22,461,517			22,210,816			22,287,638			22,153,259

See notes to condensed consolidated financial statements.

-4-

PHARMA-BIO SERV, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Three months ended July 31,						Nine months ended July 31,
	2009			2008			2009			2008
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	53,289		$	514,878		$	340,686		$	1,142,785
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Gain on disposition of property and equipment		-			-			(6,081	)		-
Stock-based compensation		11,290			41,954			47,256			116,972
Depreciation and amortization		71,370			54,046			236,900			157,745
Imputed interest expense		-			44,600			43,108			173,766
Decrease (increase) in accounts receivable		45,065			(866,618	)		1,078,501			(540,304	)
(Increase) decrease in other assets		(99,726	)		(60,453	)		(63,329	)		36,331
Increase (decrease) in liabilities		208,442			(210,727	)		8,578			(528,861	)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES		289,730			(482,320	)		1,685,619			558,434

CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment		(115,745	)		(41,128	)		(211,556	)		(742,598	)
Payments for business assets acquisition		-			-			(150,394	)		-
Proceeds from sale of property and equipment		-			-			12,400			-
NET CASH USED IN INVESTING ACTIVITIES		(115,745	)		(41,128	)		(349,550	)		(742,598	)

CASH FLOW FROM FINANCING ACTIVITIES:
Payments on obligations under capital lease		(5,691	)		(12,004	)		(25,978	)		(33,986	)
Proceeds from issuance of common stock		-			382,861			-			382,861
Payments to affiliate		-			-			(2,250,000	)		(2,750,000	)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES		(5,691	)		370,857			(2,275,978	)		(2,401,125	)
EFFECT OF EXCHANGE RATE CHANGES ON CASH		2,128			-			2,331			-
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		170,422			(152,591	)		(937,578	)		(2,585,289	)

CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD		1,979,990			2,359,668			3,087,990			4,792,366

CASH AND CASH EQUIVALENTS – END OF PERIOD	$	2,150,412		$	2,207,077		$	2,150,412		$	2,207,077
SUPPLEMENTAL DISCLOURES OF CASH FLOW INFORMATION:
Cash paid during the period for:
Income taxes	$	99,897		$	616,981		$	289,904		$	1,005,323
Interest	$	4,485		$	2,070		$	7,703		$	351,356

SUPPLEMENTARY SCHEDULES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Accounts payable incurred in projects in process	$	-		$	-		$	-		$	84,306
Income tax withheld by clients to be used as a credit in the Company’s income tax return	$	-		$	-		$	18,924		$	-
Obligations under capital lease incurred for the acquisition of a vehicle	$	-		$	-		$	58,970		$	33,695
Property and equipment with accumulated depreciation of $98,334 disposed during the nine month period ended in July 31, 2009	$	-		$	-		$	138,180		$	-

See notes to condensed consolidated financial statements.

-5-

PHARMA-BIO SERV, INC.

Notes To Condensed Consolidated Financial Statements

July 31, 2009

(Unaudited)

NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

ORGANIZATION

Pharma-Bio Serv, Inc. (“Pharma-Bio”) is a Delaware corporation organized on January 14, 2004. Pharma-Bio is the parent company of Pharma-Bio Serv PR, Inc. (“Pharma-PR”), a Puerto Rico corporation, Pharma-Bio Serv US, Inc. (“Pharma-US”), a Delaware corporation, and Pharma-Bio Serv Validation & Compliance Limited (“Pharma-IR”), a majority owned Irish corporation. Pharma-Bio, Pharma-PR, Pharma-US and Pharma-IR are collectively referred to as the “Company.” The Company operates in Puerto Rico, the United States and in Ireland under the name of Pharma-Bio Serv and is engaged in providing technical compliance consulting services primarily to the pharmaceutical, chemical, medical device and biotechnology industries.

Pharma-US is a wholly owned subsidiary, which was organized in Delaware in July 2008. As of July 31, 2009, this subsidiary was in development stage and has not incurred significant revenues or expenses.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The condensed consolidated balance sheet of the Company as of October 31, 2008 is derived from audited consolidated financial statements but does not include all disclosures required by generally accepted accounting principles. The unaudited interim condensed consolidated financial statements, include all adjustments, consisting of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the financial position and results of operations and cash flows for the interim periods. The results of operations for the nine months ended July 31, 2009 are not necessarily indicative of expected results for the full 2009 fiscal year.

The accompanying financial data as of July 31, 2009, and for the three-month and nine-month periods ended July 31, 2009 and 2008 has been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally contained in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes contained in our audited Consolidated Financial Statements and the notes thereto for the fiscal year ended October 31, 2008.

Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and all of its wholly owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ from these estimates.

Fair Value of Financial Instruments

The carrying value of the Company's financial instruments (excluding obligations under capital leases and amounts due to affiliate): cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, are considered reasonable estimates of fair value due to their liquidity or short-term nature. Management believes, based on current rates, that the fair value of its obligations under capital leases and amounts due to affiliate approximates the carrying amount.

-6-

Revenue Recognition

Revenue is primarily derived from: (1) time and materials contracts (representing approximately 90% of total revenues), which is recognized by applying the proportional performance model, whereby revenue is recognized as performance occurs, and (2) short-term fixed-fee contracts or "not to exceed" contracts (representing approximately 10% of total revenues), which revenue is recognized similarly, except that certain milestones also have to be reached before revenue is recognized. If the Company determines that a fixed-fee or “not to exceed” contract will result in a loss, the Company recognizes the estimated loss in the period in which such determination is made.

Cash Equivalents

For purposes of the consolidated statements of cash flows, cash equivalents include investments in a money market obligations trust that is registered under the U.S. Investment Company Act of 1940 and liquid investments with original maturities of three months or less.

Accounts Receivable

Accounts receivable are recorded at their estimated realizable value. Accounts are deemed past due when payment has not been received within the stated time period. The Company's policy is to review individual past due amounts periodically and write off amounts for which all collection efforts are deemed to have been exhausted. Due to the nature of the Company’s customers, bad debts are accounted for using the direct write-off method whereby an expense is recognized only when a specific account is determined to be uncollectible. The effect of using this method approximates that of the allowance method.

Income Taxes

The Company follows the provisions of Statement of Financial Accounting Standards Board No. 109, "Accounting for Income Taxes," which requires an asset and liability approach method of accounting for income taxes. This method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.

Property and equipment

Owned property and equipment, and leasehold improvements are stated at cost. Equipment and vehicles under capital leases are stated at the lower of fair market value or net present value of the minimum lease payments at the inception of the leases.

Depreciation and amortization of owned assets are provided for, when placed in service, in an amount sufficient to relate the cost of depreciable assets to operations over their estimated service lives, using a straight-line basis. Assets under capital leases and leasehold improvements are amortized, over the shorter of the estimated useful lives of the assets or initial lease term. Major renewals and betterments that extend the life of the assets are capitalized, while expenditures for repairs and maintenance are expensed when incurred. As of July 31, 2009 and October 31, 2008, the accumulated depreciation and amortization amounted to $595,318 and $480,085, respectively.

The Company evaluates for impairment its long-lived assets to be held and used, and long-lived assets to be disposed of, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Based on management estimates, no impairment of the operating properties was present.

Intangible assets

Definite-lived intangible assets, such as customer lists and covenants not to compete, are amortized on a straight-line basis over their estimated useful lives. The Company continually evaluates the reasonableness of the useful lives of these assets.

-7-

Stock-based Compensation

SFAS 123R requires that all stock-based compensation expense be recognized in the consolidated financial statements based on the fair value of the awards. Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period, and includes an estimate of awards that will be forfeited. The Company calculates the fair value of stock options using the Black-Scholes option-pricing model at grant date. SFAS 123R also amends SFAS No. 95, “Statement of Cash Flows”, to require that excess tax benefits related to stock-based compensation be reflected as cash flows from financing activities rather than cash flows from operating activities. The Company does not recognize such cash flow from financing activities since there has been no tax benefit related to the stock-based compensation.

Income Per Share of Common Stock

Basic income per share of common stock is calculated dividing net income by the weighted average number of shares of common stock outstanding. Diluted income per share includes the dilution of common stock equivalents.

The diluted weighted average shares of common stock outstanding were calculated using the treasury stock method for the respective periods.

Foreign Operations

The functional currency of the Company’s foreign subsidiary is its local currency. The assets and liabilities of the Company’s foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for subsidiaries using a functional currency other than the U.S. dollar is included as a cumulative translation adjustment in stockholders’ equity and as a component of comprehensive income.

The Company’s intercompany accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in stockholders’ equity and as a component of comprehensive income, while gains and losses resulting from the remeasurement of intercompany receivables from those international subsidiaries for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statements of operations. The net gains and losses recorded in the consolidated statements of income were not significant for the periods presented.

Reclassifications

Certain reclassifications have been made to the July 31, 2008 condensed consolidated financial statements to conform them to the July 31, 2009 condensed consolidated financial statements presentation. Such reclassifications do not affect net income as previously reported.

NOTE B - RECENT ACCOUNTING PRONOUNCEMENTS

1. In June 2009, the FASB issued SFAS No. 168 “The FASB Accounting Standards Codification™ and the Hierarchy of Generally Accepted Accounting Principles—a replacement of FASB Statement No. 162 ” (“SFAS 168”), which will be effective for interim and annual periods ending after September 15, 2009. The FASB Accounting Standards Codification (“Codification”) will become the source of authoritative GAAP recognized by the FASB. Rules and interpretive releases of the Securities and Exchange Commission (“SEC”) under authority of federal securities laws continue to be sources of authoritative GAAP for SEC registrants. All existing FASB accounting standards and guidance are superseded as described in SFAS 168. Subsequently, instead of issuing new accounting standards in the form of statements, FASB staff positions, and Emerging Issues Task Force (“EITF”) abstracts, the FASB will issue Accounting Standards Updates that will update the Codification. Adoption of the Codification will not have a significant impact on our financial statements.

-8-

2. In December 2007, the Financial Accounting Standards Board (FASB) issued SFAS No. 141R, Business Combinations (“SFAS 141R”). SFAS 141R requires: the assets acquired and liabilities assumed to be measured at fair value as of the acquisition date; liabilities related to contingent consideration to be remeasured at fair value at each subsequent reporting period; and acquisition-related costs to be expensed as these are incurred. SFAS 141R also requires additional disclosures of information surrounding a business combination. The provisions of SFAS 141R are effective for fiscal years beginning on or after December 15, 2008 and apply to business combinations that are completed on or after the date of adoption. The Company has not yet adopted this pronouncement, but expects that the nature and magnitude of the specific effects will depend upon the nature, terms and size of the acquisitions the Company completes after the effective date, if any.

3. In December 2007, the FASB issued Statement No. 160 “Noncontrolling Interests in Consolidated Financial Statements - an amendment of ARB No. 51”. This Statement applies to all entities that prepare consolidated financial statements, but will affect only those entities that have an outstanding noncontrolling interest in one or more subsidiaries or that deconsolidate a subsidiary. This statement is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. Earlier adoption is prohibited.

4. In February 2007, the FASB issued Statement No. 159 “The Fair Value Option for Financial Assets and Financial Liabilities - Including an Amendment of FASB Statement No. 115”. This Statement permits entities to choose to measure many financial instruments and certain other items at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. This Statement is expected to expand the use of fair value measurement, which is consistent with the FASB’s long-term measurement objectives for accounting for financial instruments. This Statement is effective as of the beginning of an entity’s first fiscal year that begins after November 15, 2007. The application of this standard had no significant effect on the Company's consolidated financial statements.

5. In September 2006, the FASB issued Statement No. 157 “Fair Value Measurement”. This Statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This Statement applies under other accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute. Accordingly, this Statement does not require any new fair value measurements. However, for some entities, the application of this Statement will change current practice. The changes to current practice resulting from the application of this Statement relate to the definition of fair value, the methods used to measure fair value, and the expanded disclosures about fair value measurements. This Statement is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The provisions of this Statement should be applied prospectively as of the beginning of the fiscal year in which this Statement is initially applied, except for certain exceptions stated in the Statement. The application of this standard had no significant effect on the Company's consolidated financial statements.

6. Other recently issued FASB Statements or Interpretations, SEC Staff Accounting Bulletins, and AICPA Emerging Issue Task Force Consensuses have either been implemented or are not applicable to the Company.

NOTE C - INCOME TAXES

The Company adopted the provisions of FIN 48 which includes a two-step approach to recognizing, de-recognizing and measuring uncertain tax positions accounted for in accordance with SFAS 109. As of July 31, 2009, the Company had no significant uncertain tax positions that would be reduced as a result of a lapse of the applicable statute of limitations.

On July 2008, Pharma-Bio and Pharma-PR obtained a Grant of Industrial Tax Exemption (“the Grant”) from the Puerto Rico Industrial Development Company pursuant to the terms and conditions set forth in Act No. 135 of December 2, 1997, as amended. The Grant provides relief on various Puerto Rico taxes, including income tax, mostly for the Company's new microbiological testing facility and service activities outside of Puerto Rico. The Grant is effective as of September 1, 2007 and covers a ten year period. Activities covered by the Grant are subject to a reduced income tax rate of 7%.

The operations carried out in the United States by the Company’s subsidiary are taxed in the United States. With certain limitations, the Company receives a credit on its Puerto Rico tax for the federal income tax paid. Also, upon distribution of earnings by the Puerto Rican subsidiary to its parent those dividends are taxed at the federal level, however, the parent is able to receive a credit for the taxes paid by the subsidiary on its operations in Puerto Rico, to the extent of the federal taxes that result from those earnings (determined at rates which are normally lower than in Puerto Rico). As a result, the income tax expense of the Company, under its present corporate structure, would normally be the Puerto Rico taxes on operations in Puerto Rico, plus 10% withholding in Puerto Rico from dividends paid to the Puerto Rican subsidiary’s parent, plus federal taxes on operations in the United States.

-9-

Deferred income tax assets and liabilities are computed for differences between the consolidated financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income.

The Company has not recognized deferred income taxes on undistributed earnings of its Puerto Rican subsidiary, since such earnings are considered to be reinvested indefinitely. If the earnings were distributed in the form of dividends, the Company would be subject to a tollgate tax.

Pharma-Bio and Pharma-IR have unused operating losses which result in a potential deferred tax asset. However, an allowance has been provided covering the total amount of such balance since it is uncertain whether the net operating losses can be used to offset future taxable income before their expiration dates. Realization of future tax benefits related to a deferred tax asset is dependent on many factors, including the company’s ability to generate taxable income. Accordingly, the income tax benefit will be recognized when realization is determined to be more probable than not. These net operating losses are available to offset future taxable income which expires for Pharma-Bio in 2026 while for Pharma-IR are available indefinitely.

The statutory income tax rate differs from the effective rate mainly due to the new operation in Ireland which does not have previous taxable income where its current net operating losses could be carried back and derive a tax benefit. As previously mentioned, it is company policy to recognize tax benefits of net operating loss carryforwards when realization is determined to be more probable than not.

The Company files income tax returns in the United States (federal and various states jurisdictions), Puerto Rico and Ireland. The 2003 through 2008 tax years are open and may be subject to potential examination in one or more jurisdictions. The Company is not currently under income tax examination.

NOTE D - DUE TO AFFILIATE

Pursuant to a plan and agreement of merger dated January 25, 2006, the Company agreed to pay its then sole stockholder of Pharma-PR three installments of $2,750,000 on January 25, 2007, 2008 and 2009, including imputed interest of 6.72%. In January 2009, the Company made a payment of $2,250,000 towards the final installment due on January 25, 2009. The Company expects to pay the remaining balance during fiscal year 2009. As of July 31, 2009 and October 31, 2008 the outstanding installment balances were:

	July 31, 2009			October 31, 2008
Amount due within the year ended October 31, 2009	$	500,000		$	2,750,000
Less imputed interest		-			(43,108	)
Present value of amount due		500,000			2,706,892
Current portion		(500,000	)		(2,706,892	)
Long-term portion	$	-		$	-

NOTE E – WARRANTS

At July 31, 2009 and October 31, 2008 the Company had outstanding warrants to purchase 11,053,216 shares of the Company’s common stock at prices ranging from $0.06 to $1.65 per share. The warrants became exercisable at various dates commencing in 2004 and expire at various dates through 2014.

On January 23, 2009, the Board of Directors of the Company authorized a one year extension on the expiration date of the outstanding warrants issued pursuant to, and subject to the terms and conditions of, those certain Series C Common Stock Purchase Warrants of the Company, dated as of January 25, 2006, and which were set to expire on January 24, 2009. In total, this extension of the expiration date of the common stock purchase warrants identified above will apply to an aggregate of 973,225 warrants. These warrants have an exercise price of $0.7344.

-10-

NOTE F – EARNINGS PER SHARE

The following data shows the amounts used in the calculations of basic and diluted earnings per share.

	Three months ended July 31,				Nine months ended July 31,
	2009		2008		2009		2008
Net income available to common equity holders - used to compute basic and diluted earning per share	$	53,289	$	514,878	$	340,686	$	1,142,785
Weighted average number of common shares - used to compute basic earning per share		20,751,215		19,892,186		20,751,215		19,708,428
Effect of warrants to purchase common stock		1,710,302		2,318,630		1,536,423		2,444,831
Effect of options to purchase common stock		-		-		-		-
Weighted average number of shares - used to compute diluted earnings per share		22,461,517		22,210,816		22,287,638		22,153,259

Warrants for the purchase of 8,972,625 shares of common stock for the three-month and nine-month periods ended in July 31, 2009 and 2008, were not included in computing diluted earnings per share because their effects were antidilutive. In addition, options for the purchase of 1,347,913 shares of common stock for the three-month and nine-month periods ended in July 31, 2009, and 1,506,772 shares of common stock for the three-month and nine-month periods ended in July 31, 2008, were not included in computing diluted earnings per share because their effects were also antidilutive.

NOTE G - CONCENTRATIONS OF RISK

Cash and cash equivalents

The Company maintains cash deposits in an FDIC insured bank and in a money market obligations trust, registered under the US Investment Company Act of 1940, as amended. The bank deposit balances frequently exceed federally insured limits. The money market fund is insured until September 18, 2009 under the United States Treasury Temporary Guarantee Program. No losses have been experienced or are expected on these accounts.

Accounts receivable and revenues

Management deems all its accounts receivable to be fully collectible, and, as such, does not maintain any allowances for uncollectible receivables.

The Company's revenues, and the related receivables, are concentrated in the pharmaceutical industry in Puerto Rico, the United States of America and Ireland. Although a few customers represent a significant source of revenue, the Company’s functions are not a continuous process, accordingly, the client base for which the services are typically rendered, on a project-by-project basis, changes regularly.

The Company provided a substantial portion of its services to three customers, which accounted for 10% or more of its revenues in the three-month and nine-month periods ended July 31, 2009 and 2008. During the three months ended July 31, 2009, revenues from these customers were 22%, 17%, and 9%, or a total of 48%, as compared to the same period last year for 28%, 31%, and 9%, or a total of 68%, respectively. For the nine months ended July 31, 2009 revenues from these customers were 24%, 21%, and 11%, or a total of 56%, as compared to the same period last year for 27%, 29%, and 8%, or a total of 64%, respectively. At July 31, 2009 amounts due from these customers represented 41% of the Company’s total accounts receivable balance.

-11-

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion of our results of operations and financial condition should be read in conjunction with the financial statements and the related notes included under Part I Item 1 of this Quarterly Report on Form 10-Q. In addition, reference should be made to our audited Consolidated Financial Statements and notes thereto and related Management’s Discussion and Analysis appearing in our Annual Report on Form 10-K for the year ended October 31, 2008. The following discussion includes forward-looking statements. For a discussion of important factors that could cause actual results to differ from results discussed in the forward-looking statements, see “Forward Looking Statements” below and the “Risk Factors” section in our Annual Report on Form 10-K for the year ended October 31, 2008.

Overview

We are a compliance services consulting firm with headquarters in Puerto Rico, servicing the Puerto Rico, United States and Europe markets. The compliance consulting service sector in those markets consists of local compliance and validation consulting firms, United States dedicated validation and compliance consulting firms and large publicly traded and private domestic and foreign engineering and consulting firms. We provide a broad range of compliance related consulting services. We market our services to pharmaceutical, chemical, biotechnology and medical devices, and allied products companies in Puerto Rico, the United States and Europe. Our staff includes more than 110 experienced engineering and life science professionals, and includes former quality assurance managers or directors, and experienced and trained professionals with bachelors, masters and doctorate degrees in health sciences and engineering.

We expanded the markets we serve from Puerto Rico to the United States and Ireland. We have offices in the United States and Ireland markets since fiscal years 2006 and 2008, respectively. The recently established Ireland operation, with an Ireland based management team reporting to our headquarters, has established a network of potential key customers and contacts that serve as the base for our sales target and opportunities. We are actively pursuing to further expand our US market. Since the end of our first quarter of the current fiscal year we have strengthened the US operation. Senior management and a recently hired Business Development Manager for the US operation have been leading the efforts for the US market expansion.

We have plans to further penetrate the markets we currently serve. We market our services with an active presence in industry trade shows, professional conventions, industry publications and company provided seminars to the industry. Our senior management is also actively involved in the marketing process, especially in marketing to major accounts. Our senior management and staff also concentrate on developing new business opportunities and focus on the larger customer accounts (by number of professionals or dollar volume) and responding to prospective customers’ requests for proposals.

While our core business is FDA and international agencies regulatory compliance related services, we feel that our clients are in need of other services that we can provide and allow us to present the company as a global solution provider with a portfolio of integrated services that will bring value added solutions to our customers. Accordingly, in fiscal year 2009 we have expanded our portfolio of services to include a microbiological testing laboratory, an information technology consulting practice and a training center that provides seminars/trainings to the industry.

Our new microbiological laboratory (“Lab”) located in Puerto Rico, with an investment of $1.3 million, incorporates the latest technology and test methodologies meeting pharmacopoeia industry standards and regulations. The Lab offers microbiological testing and related services to our core industries already serviced as well as the cosmetic and food industries. We have plans to expand our Lab services to include chemistry and environmental testing at an approximate investment of $185,000 which is being incurred during the second half of fiscal year 2009.

During 2008, we identified the industry need, and the opportunity to provide, technical seminars/trainings that will incorporate the latest regulatory trends and standards as well as other related areas. A network of leading industry professional experts in their field, which includes resources of our own, were identified and teamed to provide these seminars/trainings to the industry through our newly created “Pharma Serv Academy” division. Our goal is to provide these services and market our company in the markets we currently serve as well as others.

-12-

In December 2008, we acquired the operations and assets of Integratek Corp. (“Integratek”), an information technology services and consulting firm based in Puerto Rico. Integratek provides a variety of information technology services such as web pages and portals development, digital art design, intranets, extranets, software development including database integration, Windows and web applications development, software technical training and learning management systems, technology project management, and compliance consulting services, among others. Integratek is a Microsoft Certified Partner and a reseller for technology products from leading vendors in the market. Although this acquired operation is currently small, our goal is to broaden the portfolio of services that we can provide to our customer base and also target other potential customers in other industries.

In line with the strategy to penetrate the United States market, on July 1, 2009 we obtained the renewal of the certification as a "minority-controlled company" as defined by the National Minority Supplier Development Council and Growth Initiative ("NMSDC"). The certification allows us to participate in corporate diversity programs available from various potential customers in the United States and Puerto Rico. The certification is subject to renewal on July 1, 2010.

On July 2008, Pharma-Bio and Pharma-PR obtained a Grant of Industrial Tax Exemption (“the Grant”) from the Puerto Rico Industrial Development Company pursuant to the terms and conditions set forth in Act No. 135 of December 2, 1997, as amended. The Grant provides relief on various Puerto Rico taxes, including income tax, mostly for our new Lab and service activities outside of Puerto Rico. The Grant is effective as of September 1, 2007 and covers a ten year period. Activities covered by the Grant are subject to a reduced income tax rate of 7%.

Although we believe we have instituted the right strategies to be profitable and seek growth, we cannot control the fact that the industry and the local and global economies are undergoing a recession and that has affected our operation and business growth.

The global economic recession and the industry worldwide consolidation continue to affect our fiscal year 2009 revenues and our growth plans. For the nine months period ended in July 31, 2009 our total net revenues decreased by approximately $2.8 million or 24.7%, when compared to the same period last year. In order to maintain volume in the markets we serve and ensure we are price competitive, we have adjusted our pricing and gross margin structure accordingly. In addition, we implemented cost containment measures and have refocused the overall operations strategy to reduce our overhead costs. Among others, we have reduced management salaries, including those of our headquarters team. These factors have lead our net income for the nine months period ended July 31, 2009 to be approximately $341,000, a decline of $802,000 or a reduction in profit margin of 6.1 percentage points when compared to the same period last year.

The following table sets forth information as to our revenue for the three-month and nine-month periods ended July 31, 2009 and 2008, by geographic regions (dollars in thousands).

	Three months ended July 31,								Nine months ended July 31,
Revenues by Region:	2009				2008				2009				2008
Puerto Rico	$	1,934	73.6	%	$	2,888	68.9	%	$	6,388	73.8	%	$	8,173	71.1	%
United States		405	15.5	%		1,218	29.0	%		1,658	19.1	%		3,209	27.9	%
Ireland		287	10.9	%		86	2.1	%		614	7.1	%		112	1.0	%
	$	2,626			$	4,192			$	8,660			$	11,494

We believe the remainder of our fiscal year 2009 profitability and liquidity is going to be highly dependent of the effect the global economy, changes in tax laws and worldwide industry consolidations will have over our operations, and our ability to seek service opportunities and adapt to the current industry trends.

-13-

Results of Operations

The following table sets forth our statements of operations for the three-month and nine month periods ended July 31, 2009 and 2008, (dollars in thousands) and as a percentage of revenue:

	Three months ended July 31,								Nine months ended July 31,
	2009				2008				2009					2008
Revenues	$	2,626	100.0	%	$	4,192	100.0	%	$	8,660		100.0	%	$	11,494	100.0	%
Cost of services		1,753	66.8	%		2,548	60.8	%		5,732		66.2	%		7,130	62.0	%
Gross profit		873	33.2	%		1,644	39.2	%		2,928		33.8	%		4,364	38.0	%
Selling, general and administrative costs		710	27.0	%		802	19.1	%		2,209		25.5	%		2,304	20.0	%
Interest expense		5	0.2	%		46	1.1	%		51		0.6	%		180	1.6	%
Interest income		5	-0.2	%		11	-0.3	%		21		-0.2	%		69	-0.6	%
Loss (gain) on disposition of property		-	0.0	%		-	0.0	%		(6	)	-0.1	%		-	0.0	%
Income before income taxes		163	6.2	%		807	19.3	%		695		8.0	%		1,949	17.0	%
Income tax expense		110	4.2	%		292	7.0	%		354		4.1	%		806	7.0	%
Net income		53	2.0	%		515	12.3	%		341		3.9	%		1,143	10.0	%

Revenues. Revenues for the three months ended July 31, 2009 were $2.6 million, a decrease of approximately $1.6 million or 37.3%, when compared to the same period last year. The reduction is mainly attributable to the decrease of approximately $1.3 million and $0.8 million in the Puerto Rico and the United States market consulting service revenue, respectively, partially offset by $0.2 million generated by the Ireland consulting operation, $0.2 million derived from our new Lab operation and $0.1 million from the Integratek division.

For the nine-month period ended July 31, 2009 revenues were $8.7 million, a net decrease of approximately $2.8 million or 24.7% from the comparable nine-month period last year. The reduction is mainly attributable to the decrease in Puerto Rico and the United States market consulting service revenues of $2.6 million and $1.5 million, respectively, partially offset by $0.5 million generated by the Ireland consulting operation, $0.6 million in new business from our Lab and $0.2 million from our Integratek division.

Decreases in the service revenue are mostly due to the global economic recession and the closing of, or decrease in, operations of some pharmaceutical plants, triggered by operations consolidation.

Cost of Services; gross margin. The overall gross margin for the three-month period ended in July 31, 2009 reflected a gross margin reduction of 6.0 percentage points when compared to the same period last year. The decrease is attributable to the effect over gross margin of the consulting and Lab operations by 3.4 and 2.6 percentage points, respectively.

The gross margin for the nine-month period ended in July 31, 2009 reflected a net reduction of 4.2 percentage points when compared to the same period last year. The decrease is attributable to the effect over gross margin of 3.0 and 1.2 percentage points from the consulting and Lab operations, respectively.

The decline in gross margin ratios for the three and nine month periods ended in July 31, 2009, as compared to last year, is mainly attributable to our strategy to maintain volume in the consulting market we serve by keeping our prices competitive, and the Lab’s low gross margin yield as a function of billings versus fixed costs of services.

Selling, General and Administrative Expenses. Selling, general and administrative expenses for the three and nine month periods ended in July 31, 2009 were approximately $710,000 and $2.2 million, respectively, a net reduction in expenses of approximately $92,000 and $95,000, respectively, as compared to the same periods last year.

The reduction in selling general and administrative expenses for the three and nine month periods ended in July 31, 2009, as compared to last year, is mainly attributable to the net savings attained in salary adjustments to our management team and other cost containment measures implemented, partially offset by expenses incurred by our new Integratek, Lab, Pharma Serv Academy and Ireland operations.

Interest Expense. We have been recognizing imputed interest expense incurred in connection with the long-term obligations originated pursuant to a plan and agreement of merger dated January 25, 2006 for the acquisition of Pharma-PR. This expense decreases as annual payments are made through fiscal year 2009. Interest expense savings for the three and nine months periods ended in July 31, 2009 as compared to the same periods last year were approximately $41,000 and $129,000, respectively.

-14-

Income Taxes Expense. The decrease in income taxes expense is attributable to the decrease of income before income tax. The statutory income tax rate differs to the effective rate mainly due to the new operation in Ireland which does not have previous taxable income where its current net operating loss could be carried back and derive a tax benefit. Income tax benefits will be recognized when realization is determined to be more probable than not. Realization of future tax benefits is dependent on many factors, including the tax activity ability to generate taxable income.

Net Income. Our net income for the three and nine month periods ended July 31, 2009 were approximately $53,000 and $341,000, respectively, a decline of $462,000 and $802,000 or a reduction in profit margin of 10.3 and 6.1 percentage points, respectively, when compared to the same periods last year.

For the three months period ended in July 31, 2009, earnings per common share basic and diluted were $0.003 and $0.002, a decline of $0.023 and $0.021, respectively, when compared to the same period last year. For the nine months period ended in July 31, 2009, earnings per common share basic and diluted were $0.016 and $0.015, a decline of $0.042 and $0.037, respectively, when compared to the same period last year.

Our net income was affected by the decrease in overall gross margin, new operations selling general and administrative expenses partially offset by cost containment measures, favorable variances in interest expense, and the reduction of income tax expense due to the decline in taxable income.

Liquidity and Capital Resources

Liquidity is a measure of our ability to meet potential cash requirements, including planned capital expenditures. For the nine months ended July 31, 2009, we have generated cash flow from operations of approximately $1.7 million and sustain working capital of approximately $2.8 million, notwithstanding within that period we have made a partial payment of $2.25 million related to the final $2.75 million installment due in January 2009 pursuant to the 2006 Pharma-PR acquisition agreement. During the remainder of fiscal year 2009 we expect to pay from working capital the remaining balance of $500,000 related to the Pharma-PR acquisition agreement and $50,000 pertaining to the acquisition of Integratek.

Our primary cash needs consist of the payment of compensation to our professional staff, overhead expenses, statutory taxes, and payments pursuant to the agreement terms for the acquisition of Pharma-PR and Integratek.

Management believes that with the current level of operations and cash flows from operations, the collectability of high quality customer receivables will be sufficient to fund anticipated expenses and satisfy other possible long-term contractual commitments, including our obligations to pay the balance of the final installment due in connection with the acquisition of Pharma-PR and the acquisition of Integratek, for the next twelve months.

To the extent that we pursue possible opportunities to expand our operations, either by acquisition or by the establishment of operations in a new locale, we will incur additional overhead, and there may be a delay between the period we commence operations and our generation of net cash flow from operations.

While uncertainties relating to the current local and global economic condition, competition, the industries and geographical regions served by us and other regulatory matters that exist within the consulting services industry, management is implementing marketing and cost containment strategies to seek and improve our sales, current liquidity and profitability trend.

Off-Balance Sheet Arrangements

We were not involved in any significant off-balance sheet arrangement during the nine months ended July 31, 2009.

Critical Accounting Policies and Estimates

There were no material changes during the nine months ended July 31, 2009 to the critical accounting policies reported in our Annual Report on Form 10-K for the fiscal year ended October 31, 2008.

New Accounting Pronouncements

There were no new accounting pronouncements, issued since our filing of the Annual Report on Form 10-K for the fiscal year ended October 31, 2008, which could have a significant effect on our condensed consolidated financial statements.

-15-

Forward-Looking Statements

Our business, financial condition, results of operations, cash flows and prospects, and the prevailing market price and performance of our common stock, may be adversely affected by a number of factors, including the matters discussed below. Certain statements and information set forth in this Quarterly Report on Form 10-Q, as well as other written or oral statements made from time to time by us or by our authorized executive officers on our behalf, constitute “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These statements include all statements other than those made solely with respect to historical fact and identified by words such as “believes”, “anticipates”, “expects”, “intends” and similar expressions, but such words are not the exclusive means of identifying such statements. We intend for our forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we set forth this statement and these risk factors in order to comply with such safe harbor provisions. You should note that our forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q or when made and we undertake no duty or obligation to update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. Although we believe that the expectations, plans, intentions and projections reflected in our forward-looking statements are reasonable, such statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The risks, uncertainties and other factors that our stockholders and prospective investors should consider include, but are not limited to, the following:

	·	Because our business is concentrated in the pharmaceutical industry in Puerto Rico, any changes in that industry could impair our ability to generate revenue and realize a profit.
	·	Because our business is dependent upon a small number of clients, the loss of a major client could impair our ability to operate profitably.
	·	Since our business is dependent upon the development and enhancement of patented pharmaceutical products or processes by our clients, the failure of our clients to obtain and maintain patents could impair our ability to operate profitably.
	·	We may be unable to pass on increased labor costs to our clients.
	·	Our cash requirements include payments due from our reverse merger transaction.
	·	Consolidation in the pharmaceutical industry may have a harmful effect on our business.
	·	Because the pharmaceutical industry is subject to government regulations, changes in government regulations relating to this industry may affect the need for our services.
	·	Changes in tax benefits may affect the willingness of companies to continue or expand their operations where we do business.
	·	Puerto Rico’s economy, including its governmental financial crisis, may affect the willingness of businesses to commence or expand operations in Puerto Rico.
	·	Other factors, including economic factors, may affect the decision of businesses to continue or expand their operations in Puerto Rico.
	·	If we are unable to protect our clients’ intellectual property, our ability to generate business will be impaired.
	·	We may be subject to liability if our services or solutions for our clients infringe upon the intellectual property rights of others.
	·	We may be held liable for the actions of our employees or contractors when on assignment.
	·	To the extent that we perform services pursuant to fixed-price or incentive-based contracts, our cost of services may exceed our revenue on the contract.
	·	Because most of our contracts may be terminated on little or no advance notice, our failure to generate new business could impair our ability to operate profitably.
	·	Because we are dependent upon our management, our ability to develop our business may be impaired if we are not able to engage skilled personnel.
	·	We may not be able to continue to grow unless we consummate acquisitions or enter markets outside of Puerto Rico.
	·	If we identify a proposed acquisition, we may require substantial cash to fund the cost of the acquisition.
	·	If we make any acquisitions, they may disrupt or have a negative impact on our business.
	·	Because of our cash requirements, we may be unable to pay dividends.
	·	Because there is a limited market in our common stock, stockholders may have difficulty in selling our common stock and our common stock may be subject to significant price swings.
	·	Our quarterly revenues, operating results and profitability will vary from quarter to quarter, which may result in increased volatility of our stock price.
	·	The issuance of securities, whether in connection with an acquisition or otherwise, may result in significant dilution to our stockholders.

-16-

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report.

Changes in Internal Control Over Financial Reporting

Based on an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, there has been no change in our internal control over financial reporting during our last fiscal quarter identified in connection with that evaluation that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

-17-

PART II– OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

From time to time, we may be a party to legal proceedings incidental to our business. We do not believe that there are any proceedings threatened or pending against us, which, if determined adversely to us, would have a material effect on our financial position or results of operations and cash flows.

ITEM 6. EXHIBITS

(a) Exhibits:

31.1

Certification of chief executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Certification of the chief executive officer and chief financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

-18-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PHARMA-BIO SERV, INC.

	/s/ Elizabeth Plaza
	Elizabeth Plaza
	Chief Executive Officer
	(Principal Executive Officer)

	/s/ Pedro J. Lasanta
	Pedro J. Lasanta
	Chief Financial Officer
	(Principal Financial Officer and Principal Accounting Officer)

Dated: September 14, 2009

-19-